Role of Tepotinib, Capmatinib and Crizotinib in non-small cell lung cancer

Abstract

c-MET is a receptor tyrosine kinase involved in cell proliferation. However, when c-MET is abnormally activated, it becomes a carcinogen through some genetic mechanism. Mutation of METex14 is one of the reasons of abnormal activation of MET, which has been found in non-small cell lung cancer (NSCLC) patients. NSCLC is unresectable, prone to recurrence, and threatens the life of patients. Currently, only a few multi-targeted drugs are available to treat the disease. This review summarizes the effect of three targeted drugs on NSCLC. The drug tepotinib has shown promising clinical effects in the treatment of NSCLC by inhibiting MET mutations. Crizotinib is a drug widely used to treat NSCLC, but it needs to be determined whether crizotinib is effective in other cancers. Capmatinib is also a MET inhibitor, which has high selectivity and powerful curative effect, as well as safety in clinical trials. Further studies are needed to explore the clinical application of tepotinib, capmatinib, and crizotinib.